Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $3.3B | $3.1B | $2.9B | $3.0B | $2.9B | $2.8B | $2.1B | $1.8B | $1.7B | $1.6B | $1.5B | $1.4B | $1.4B | $1.4B | $1.3B | $1.2B | $1.1B | $1.1B | $1.1B | $1.0B | $913M |
| Bruttoergebnis | $1.2B | $1.1B | $1.0B | $1.1B | $1.1B | $1.2B | $768M | $609M | $546M | $513M | $501M | $456M | $448M | $435M | $388M | $339M | $318M | $304M | $303M | $292M | $262M |
| Bruttomarge % | 36.8% | 35.9% | 34.6% | 38.4% | 39.5% | 41.4% | 35.8% | 33.0% | 31.8% | 32.1% | 33.2% | 32.6% | 31.5% | 31.8% | 30.6% | 28.4% | 28.7% | 28.8% | 28.8% | 28.6% | 28.7% |
| Betriebsergebnis (EBIT) | $700M | $617M | $595M | $711M | $764M | $759M | $419M | $297M | $255M | $229M | $197M | $129M | $182M | $162M | $136M | $116M | $106M | $106M | $125M | $113M | $106M |
| Operative Marge % | 21.1% | 20.1% | 20.6% | 24.1% | 26.5% | 26.8% | 19.5% | 16.1% | 14.8% | 14.3% | 13.0% | 9.2% | 12.8% | 11.9% | 10.8% | 9.7% | 9.6% | 10.0% | 11.8% | 11.1% | 11.6% |
| Jahresüberschuss | $565M | $494M | $493M | $593M | $586M | $662M | $346M | $242M | $207M | $151M | $144M | $96M | $127M | $112M | $81M | $76M | $65M | $73M | $86M | $71M | $67M |
| Nettomarge % | 17.0% | 16.1% | 17.0% | 20.1% | 20.3% | 23.4% | 16.1% | 13.1% | 12.0% | 9.4% | 9.5% | 6.8% | 8.9% | 8.2% | 6.4% | 6.3% | 5.9% | 6.9% | 8.2% | 6.9% | 7.3% |
| EBITDA | — | $724M | $744M | $844M | $808M | $880M | $519M | $403M | $353M | $326M | $288M | $218M | $272M | $248M | $200M | $183M | $161M | $166M | $186M | $158M | $150M |
| Ergebnis je Aktie (EPS) | $7.82 | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 | $4.57 | $3.21 | $2.74 | $1.99 | $1.91 | $1.30 | $1.75 | $1.57 | $1.12 | $1.02 | $0.89 | $1.00 | $1.19 | $0.98 | $1.00 |
| Ausstehende Aktien (Mio.) | — | 73M | 74M | 75M | 76M | 76M | 76M | 75M | 75M | 76M | 75M | 74M | 73M | 71M | 72M | 74M | 73M | 73M | 72M | 72M | 67M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für WST. /companies/us/WST
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms